Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024

Core Insights - Atea Pharmaceuticals is advancing the combination of bemnifosbuvir and ruzasvir as a potential treatment for Hepatitis C Virus (HCV), with upcoming presentations at The Liver Meeting 2024 [1][2] Company Overview - Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing oral antiviral therapies for serious viral infections, leveraging a proprietary nucleos(t)ide prodrug platform [7] Product Development - Bemnifosbuvir is a nucleotide analog polymerase inhibitor that has shown to be approximately 10-fold more active than sofosbuvir against various HCV strains and has a favorable pharmacokinetic profile supporting once-daily dosing [3] - Ruzasvir, an NS5A inhibitor, has demonstrated potent antiviral activity and a favorable safety profile in clinical studies, also supporting once-daily dosing [4] Clinical Trials - The combination of bemnifosbuvir and ruzasvir is currently in Phase 2 development for HCV, with results expected to be reported later this year and plans to advance into Phase 3 development [2][8] Market Need - The high incidence rate of HCV infections highlights the urgent need for new therapies, particularly for patients with substance abuse disorders and comorbidities [2][5] - Globally, an estimated 50 million people live with chronic HCV infection, with around 1 million new infections and 242,000 deaths annually [5][6]